| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
11,619 |
9,610 |
$474K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
8,091 |
1,602 |
$411K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
6,317 |
4,864 |
$212K |
| 80053 |
Comprehensive metabolic panel |
9,976 |
9,056 |
$104K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
630 |
616 |
$89K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
1,474 |
1,317 |
$62K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
763 |
630 |
$40K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,478 |
712 |
$31K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
697 |
601 |
$30K |
| 85027 |
|
2,563 |
2,361 |
$25K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
5,173 |
4,666 |
$23K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
1,066 |
943 |
$23K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
2,083 |
1,819 |
$20K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
125 |
124 |
$17K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,313 |
1,258 |
$14K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
332 |
301 |
$13K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
384 |
332 |
$9K |
| 84443 |
Thyroid stimulating hormone (TSH) |
501 |
489 |
$9K |
| 62323 |
|
70 |
37 |
$9K |
| 82728 |
|
388 |
383 |
$7K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
58 |
36 |
$7K |
| G0378 |
Hospital observation service, per hour |
73 |
43 |
$6K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
98 |
79 |
$5K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
95 |
27 |
$5K |
| 85007 |
|
1,605 |
1,488 |
$5K |
| 84439 |
|
283 |
278 |
$4K |
| 87632 |
|
29 |
29 |
$4K |
| 84484 |
|
450 |
368 |
$4K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
87 |
27 |
$3K |
| 81001 |
|
941 |
883 |
$3K |
| 71045 |
Radiologic examination, chest; single view |
730 |
656 |
$3K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
77 |
71 |
$3K |
| 87807 |
|
109 |
102 |
$2K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
63 |
14 |
$2K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
128 |
114 |
$2K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
32 |
28 |
$2K |
| 83880 |
|
97 |
87 |
$2K |
| 83690 |
|
215 |
200 |
$2K |
| 93296 |
|
80 |
78 |
$1K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
25 |
24 |
$1K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
19 |
18 |
$1K |
| 70450 |
Computed tomography, head or brain; without contrast material |
17 |
16 |
$1K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
29 |
29 |
$1K |
| 71046 |
Radiologic examination, chest; 2 views |
85 |
79 |
$1K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
101 |
77 |
$1K |
| 84145 |
|
56 |
48 |
$992.31 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
98 |
89 |
$938.47 |
| 81025 |
|
89 |
85 |
$852.97 |
| 83655 |
|
40 |
40 |
$743.65 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
60 |
59 |
$638.91 |
| 87040 |
|
53 |
51 |
$607.51 |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
291 |
134 |
$551.51 |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
492 |
248 |
$544.89 |
| 80061 |
Lipid panel |
48 |
46 |
$527.51 |
| 86140 |
|
48 |
43 |
$475.93 |
| 85610 |
|
170 |
144 |
$472.13 |
| 85730 |
|
113 |
103 |
$318.68 |
| 87186 |
|
35 |
33 |
$317.98 |
| 87077 |
|
42 |
40 |
$301.45 |
| 83605 |
|
49 |
47 |
$257.84 |
| 36415 |
Collection of venous blood by venipuncture |
13,090 |
11,570 |
$255.81 |
| 87486 |
|
29 |
29 |
$255.52 |
| 87581 |
|
29 |
29 |
$255.52 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
123 |
107 |
$253.46 |
| 83735 |
|
29 |
26 |
$167.62 |
| 94761 |
|
16 |
12 |
$120.74 |
| 82803 |
|
15 |
14 |
$107.30 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
18 |
13 |
$105.20 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
562 |
421 |
$99.83 |
| 87147 |
|
14 |
13 |
$87.55 |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
130 |
106 |
$82.92 |
| 81003 |
|
36 |
36 |
$78.46 |
| 87070 |
|
14 |
13 |
$74.52 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
129 |
122 |
$69.37 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
97 |
80 |
$60.95 |
| 87205 |
|
13 |
12 |
$49.51 |
| 82947 |
|
84 |
48 |
$33.03 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
70 |
56 |
$31.86 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
22 |
17 |
$31.09 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
16 |
13 |
$25.75 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
20 |
14 |
$23.20 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
51 |
48 |
$0.00 |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
16 |
16 |
$0.00 |
| A9270 |
Non-covered item or service |
101 |
73 |
$0.00 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
15 |
14 |
$0.00 |